Last update:

Weight management news

Ozempic-like drugs found to be safe and effective for children with obesity, without diabetes

New research being presented at the International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (15–17 July), shows that glucagon-like peptide-1 receptor agonists (GLP-1 ...

Q&A: Psychedelics, cannabis, GLP-1s and drug policy changes

From headlines and social media, psychedelic therapies, cannabis use and GLP-1 medications have seemingly become commonplace overnight, but the science underlying these treatments and the pathway to drug approval are often ...

Aussie supermarkets failing to help us eat a healthier diet

New research presented at this year's International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (July 15–17), reveals that few of the world's 21 largest food retailers ...

Rise of GLP-1s raises long-term affordability questions

As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022. ...

What's driving the obesity pandemic?

New research presented at the International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico, (15–17 July) asks what is driving the obesity pandemic.

Weight loss drugs could help with binge eating disorder

Drugs commonly used for weight loss, known as GLP-1 receptor agonists, have been found to reduce the key symptoms of binge eating disorder in a new review of evidence led by University College London (UCL) researchers.

Muscles matter for diabetes risk, new study finds

A major new international study led by Curtin University has found diabetes risk is about more than body weight or obesity, revealing that muscle health also likely plays a major role in whether people develop the condition.